Abstract: Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.

Abstract: Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

Abstract: Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.

Abstract: Described herein are methods and compositions related to induced alveolar epithelial type 2 cells (iAEC2s), e.g., artificially-produced epithelial type 2 cells.

Abstract: The technology described herein relates to methods and kits for directed differentation of primordial NKX2-1+ lung progenitors along proximal differentiation pathways into functional airway epithelial cells and airway organoids (“bronchospheres”) or along distal lineage pathways using modulation of Wnt signaling. Other aspects relate cell lines, methods, assays and kits comprising airway epithelial cells, and assays for diagnosing a disease that affects swelling of the bronchospheres, and/or for assessing genetic lesions and/or drugs for treating the the disease, where the disease is cystic fibrosis. Other aspects relate to personalized medicine and methods of treatment of cystic fibrosis using the airway epithelial cells.

Abstract: Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

Abstract: Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

Abstract: Described herein are methods and compositions related to induced alveolar epithelial type 2 cells (iAEC2s), e.g., artificially-produced epithelial type 2 cells.

Abstract: Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

Abstract: The technology described herein relates to methods and kits for directed differentation of primordial NKX2-1+ lung progenitors along proximal differentiation pathways into functional airway epithelial cells and airway organoids (“bronchospheres”) or along distal lineage pathways using modulation of Wnt signaling. Other aspects relate cell lines, methods, assays and kits comprising airway epithelial cells, and assays for diagnosing a disease that affects swelling of the bronchospheres, and/or for assessing genetic lesions and/or drugs for treating the the disease, where the disease is cystic fibrosis. Other aspects relate to personalized medicine and methods of treatment of cystic fibrosis using the airway epithelial cells.